PFKFB3-Inhibition während einer Radiochemotherapie des Rektumkarzinoms – Überprüfung in einem patient-derived xenograft In-vivo-Modell / vorgelegt von Marcus Edelmann ; Refererentin PD Dr. med. L. C. Conradi, Ko-Referent: Prof. Dr. med. S. Rieken, Drittreferent: Prof. Dr. med. R. Dressel
Colorectal cancer (CRC) is the third most common cancer diagnosed worldwide and the second leading cause of cancer death. Approximately 30% of colorectal carcinomas are localized in the rectum. Neoadjuvant radiotherapy (RT) or radiochemotherapy (RCT) is an integral aspect of patients’ treatment. However, Patients' response to preoperative R(C)T is heterogeneous and ranges from resistance and disease progression, despite intensive treatment up to complete tumor regression. In order to minimize the development of radiation resistance, it is important to review and optimize existing treatment ....
| Medienart: |
Buch |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
Göttingen: 2024 |
| Weitere Ausgaben: |
Erscheint auch als Online-Ausgabe: PFKFB3-Inhibition während einer Radiochemotherapie des Rektumkarzinoms – Überprüfung in einem patient-derived xenograft In-vivo-Modell |
|---|
| Sprache: |
Deutsch |
|---|
| Beteiligte Personen: |
Edelmann, Marcus, 1996- [VerfasserIn] |
|---|---|
| Hochschulschrift: |
| Themen: |
Hochschulschrift |
|---|
| Umfang: |
IV, 87 Seiten ; Illustrationen, Diagramme |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1879480255 |
|---|
| LEADER | 01000cam a2200265 4500 | ||
|---|---|---|---|
| 001 | 1879480255 | ||
| 003 | DE-627 | ||
| 005 | 20240320112127.0 | ||
| 007 | tu | ||
| 008 | 240130s2024 gw ||||| m 00| ||ger c | ||
| 035 | |a (DE-627)1879480255 | ||
| 035 | |a (DE-599)KXP1879480255 | ||
| 035 | |a (OCoLC)1419223120 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a ger | ||
| 044 | |c XA-DE-NI | ||
| 082 | 0 | |a 610 |2 22 | |
| 100 | 1 | |a Edelmann, Marcus |d 1996- |e verfasserin |0 (DE-588)1323990844 |0 (DE-627)1883895243 |4 aut | |
| 245 | 1 | 0 | |a PFKFB3-Inhibition während einer Radiochemotherapie des Rektumkarzinoms – Überprüfung in einem patient-derived xenograft In-vivo-Modell |c vorgelegt von Marcus Edelmann ; Refererentin PD Dr. med. L. C. Conradi, Ko-Referent: Prof. Dr. med. S. Rieken, Drittreferent: Prof. Dr. med. R. Dressel |
| 264 | 1 | |a Göttingen |c 2024 | |
| 300 | |a IV, 87 Seiten |b Illustrationen, Diagramme | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 502 | |b Dissertation |c Georg-August-Universität Göttingen |d 2024 | ||
| 520 | |a Colorectal cancer (CRC) is the third most common cancer diagnosed worldwide and the second leading cause of cancer death. Approximately 30% of colorectal carcinomas are localized in the rectum. Neoadjuvant radiotherapy (RT) or radiochemotherapy (RCT) is an integral aspect of patients’ treatment. However, Patients' response to preoperative R(C)T is heterogeneous and ranges from resistance and disease progression, despite intensive treatment up to complete tumor regression. In order to minimize the development of radiation resistance, it is important to review and optimize existing treatment ... | ||
| 540 | |2 cc |u http://creativecommons.org/licenses/by/4.0/ | ||
| 650 | 4 | |a Rektumkarzinom | |
| 650 | 4 | |a PFKFB3 | |
| 650 | 4 | |a Radiotherapie | |
| 650 | 4 | |a Rectal cancer | |
| 650 | 4 | |a PFKFB3 | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 4 | |a Tumor vessel normalization | |
| 655 | 7 | |a Hochschulschrift |0 (DE-588)4113937-9 |0 (DE-627)105825778 |0 (DE-576)209480580 |2 gnd-content | |
| 700 | 1 | |a Conradi, Lena-Christin |e akademischer betreuerin |4 dgs | |
| 700 | 1 | |a Rieken, Stefan |e akademischer betreuerin |4 dgs | |
| 700 | 1 | |a Dressel, Ralf |e akademischer betreuerin |4 dgs | |
| 751 | |a Göttingen |0 (DE-588)4021477-1 |0 (DE-627)106313819 |0 (DE-576)20893815X |4 uvp | ||
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |a Edelmann, Marcus, 1996 - |t PFKFB3-Inhibition während einer Radiochemotherapie des Rektumkarzinoms – Überprüfung in einem patient-derived xenograft In-vivo-Modell |d Göttingen, 2024 |h 1 Online-Ressource |w (DE-627)1879480247 |
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 951 | |a BO | ||
| 953 | |2 045F |a 610 | ||
| 980 | |2 40 |1 01 |x 0007 |b 447221136X |c 00 |f --%%-- |d 2024 B 25396 |e a |j --%%-- |y xsn |z 30-01-24 | ||
| 983 | |2 40 |1 00 |x DE-7 |8 00 |0 (DE-627)619875593 |a MED 371 |b Radiologie | ||
| 983 | |2 40 |1 00 |x DE-7 |8 01 |0 (DE-627)619875895 |a MED 424 |b Onkologie | ||
| 984 | |2 40 |1 01 |x 0007 |a 7$239018966 | ||